Dealroom and NATO Innovation Fund: European Defence, Security & Resilience Startups Smash Record with $8.7B Raised in 2025
10.2.2026 07:05:00 CET | Business Wire | Press Release
An exclusive new report by Dealroom and the NATO Innovation Fund shows that European DSR (Defence, Security and Resilience) startups secured a record $8.7 billion in venture capital in 2025. The surge was fuelled by late-stage mega-rounds to support breakthrough technologies that help address critical capabilities for NATO nations – from freedom of operations & mobility, to awareness and decision making, and the security of critical technologies.
Record funding surge powers DSR Startups to meet NATO nations’ most urgent security needs
Funding for DSR startups increased by 55% year on year and is nearly four times higher than five years ago. It outpaces the broader European VC market, which grew just 16% over the past year. The increase indicates that both innovators and investors across Europe are rallying to develop, back and scale technologies that address the capability needs of European NATO nations, while also capitalising on the opportunities generated by Allies’ pledge to invest 5% of their Gross Domestic Product in defence and security.
“Across Europe, DSR continues to scale rapidly, with business growth evident across markets and substantial venture capital deployed through large rounds,” said Sander Verbrugge, Partner, NATO Innovation Fund. “With proven revenue streams and clear trajectories for continued growth, the opportunity is now for the remainder of capital providers - from banks to private equity - to step in and support the next phase of funding for late-stage DSR companies.”
Late-stage investment tripled to $4.7B, signalling a maturing ecosystem, and was driven by investments in technologies addressing key defence and security challenges. AI dominated the sector, underpinning 44% of all DSR funding – the highest share in six years – as autonomous systems, defence optimised computing and AI-enabled decision making became critical to next-generation capabilities.
Germany and the UK lead in DSR investing, with Finland, Spain, Norway and Bulgaria on the rise
The report reveals where Europe’s DSR capital is concentrated, with the UK and Germany continuing to lead the charge and new countries emerging as regional hubs. Highlights include:
- The UK leads Europe in total VC funding for DSR startups attracting $2.9 billion in 2025 and $9.9 billion since 2020, though Germany is closing the gap with $2.1 billion raised in 2025 and $5.4 billion since 2020.
- Germany and the Netherlands recorded the highest share of national VC funding allocated to DSR companies in 2025 at over 15% each, underlining strong national commitment to the sector and alignment with industrial policy priorities.
- Central and Eastern Europe showed the fastest growth in deal velocity, with rounds increasing 2.7x since 2020.
- Munich retained its position as Europe’s leading DSR hub with $1.7 billion raised, reflecting its strong industrial base, access to defence customers and deep talent pool. Sofia and Oslo both rose in prominence, making it into the top European cities for VC investment for the first time in five years.
“Munich’s leadership is shaped by its strong industrial base, diverse international talent, and a vibrant deep tech ecosystem—all of which are driving future growth,” said Daniel Metzler, Co-Founder & CEO, Isar Aerospace. “This ecosystem is enabling next-generation space and defence companies to scale faster and move from innovation to deployment.”
Startups are growing, fostering partnerships and generating revenue at pace
Translating increased investments into real defence, security and resilience capabilities for Europe requires adoption of those technologies by governments at scale. The report shows early signs that many startups are already generating revenue, and gaining access to the full capital stack required for further growth, cementing their role in Europe’s technological sovereignty and security. Highlights include:
- Contracts and Partnerships: Though data on contracts is limited, the report reveals that defence primes are increasingly investing and establishing strategic development partnerships with DSR startups. In addition, DSR startups are increasingly winning public tenders, particularly in the drone industry.
- Access to the Full Capital Stack: Although VC financing remains the key source of income for DSR startups, debt and grants are increasing, indicating the maturing of the DSR ecosystem.
- Consolidation: M&A activity is at an all time high - 4x more than four years ago – driven by neo-primes acquiring startups to grow their offerings and expand geographically. On the other hand, no public listings took place this year, despite a flurry of listings in 2021.
“While capital continues to flow into a sector that has never been more strategically important, investment alone doesn’t automatically translate into stronger European defence capabilities. What matters is how effectively DSR startups and scaleups are turning funding into real technologies, real contracts, and real operational impact,” said John Ridge, Chief Adoption Officer, NATO Innovation Fund. “European ministries of defence have a critical role to play by making it easier for startups and scaleups to compete for acquisition contracts and by reshaping the relationships between new entrants and established defence primes.”
Click here to read the full report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260209841430/en/
Contacts
Amalia Kontesi
amalia@nif.fund
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press Release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press Release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press Release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press Release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom